On July 16, 2025, Fortress Biotech, Inc. reported AstraZeneca's update stating that its product anselamimab did not meet primary goals in a clinical trial for AL amyloidosis, despite some clinical benefits seen in a specific patient group. Fortress had previously received $57 million from the acquisition of Caelum Biosciences and could earn more based on future milestones.